Join
Live feed
·
PRReleasevia Quantisnow
Kineta Inc. logo
Kintara Therapeutics Inc. logo

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

ByQuantisnow·Wall Street's wire, on your screen.
KA· Kineta Inc.KTRA· Kintara Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KA (Kineta Inc.), KTRA (Kintara Therapeutics Inc.) and more on Quantisnow.

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer | Quantisnow